By stimulating glucose-dependent insulin secretion and suppressing glucagon production, they are a cornerstone of the treatment of type 2 diabetes (DM2), particularly in patients with a higher risk of cardiovascular disease ( This narrative review describes the complex interplay between GLP-1 signalling and intestinal inflammation, highlighting both the potential benefits and limitations of GLP1 RAs in IBD management, with a particular focus on their promising role in selected obese IBD patients
Join us to connect, grow, and support one another as you work toward a more peaceful relationship with food and your body
Summary of phase 2 clinical trials of GLP1R agonists for PD Ex-4: exenatide-4, mTOR: mechanistic target of rapamycin, IRS1: insulin receptor substrate 1, MDS-UPDRS: Movement Disorder Society-Sponsored Revision of the Unified Parkinsons Disease Rating Scale, PD: Parkinsons disease, PKB: protein kinase B, DAergic: dopaminergic, GLP1R: glucagon-like peptide-1 receptor.
Whether youre a sponsor, CRO, or site, these changes are already impacting how trials are delivered and which tools youll need to stay ahead
Ideal for improving physical performance and managing weight, easy to consume in effervescent form
Sullivan, J.D
